臨床腫瘍学次世代シーケンシング（NGS）の世界市場（～2026年）

• 英文タイトル：Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11397
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、131ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は臨床腫瘍学次世代シーケンシング（NGS）のグローバル市場について調査・分析したレポートです。種類別（NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析）市場規模、用途別（学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別臨床腫瘍学次世代シーケンシング（NGS）の競争状況、市場シェア
・世界の臨床腫瘍学次世代シーケンシング（NGS）市場：種類別市場規模 2015年-2020年（NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析）
・世界の臨床腫瘍学次世代シーケンシング（NGS）市場：種類別市場規模予測 2021年-2026年（NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析）
・世界の臨床腫瘍学次世代シーケンシング（NGS）市場：用途別市場規模 2015年-2020年（学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体）
・世界の臨床腫瘍学次世代シーケンシング（NGS）市場：用途別市場規模予測 2021年-2026年（学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体）
・北米の臨床腫瘍学次世代シーケンシング（NGS）市場分析：米国、カナダ
・ヨーロッパの臨床腫瘍学次世代シーケンシング（NGS）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの臨床腫瘍学次世代シーケンシング（NGS）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の臨床腫瘍学次世代シーケンシング（NGS）市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの臨床腫瘍学次世代シーケンシング（NGS）市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Illumina、Roche、Agilent Technologies、Knome、Genomatix Software、GATC Biotech、Oxford Nanopore Technologies、Macrogen、Life Technologies、DNASTAR、Exosome Diagnostics、Biomatters、CLC Bio、BGI、Qiagen、Perkin Elmer、Pacific Bioscience、Partek、GnuBIO、Foundation Medicine、Paradigm、Caris Life Sciences、Myriad Genetics
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.

Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
The global Clinical Oncology Next Generation Sequencing (NGS) market size is projected to reach US$ 782.8 million by 2026, from US$ 704.7 million in 2020, at a CAGR of 10.6%% during 2021-2026.

Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics

Market segment by Type, the product can be split into
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Market segment by Application, split into
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
1.4 Market by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2015-2026)
2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2015-2020)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
2.3.6 Primary Interviews with Key Clinical Oncology Next Generation Sequencing (NGS) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Market Size
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2015-2020)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2015-2020)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
3.3 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.4 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.5 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2015-2020)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in North America (2019-2020)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe (2019-2020)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

8 China
8.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China (2019-2020)
8.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
8.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan (2019-2020)
9.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
9.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
10.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

11 India
11.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India (2019-2020)
11.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
11.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
12.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America (2019-2020)
12.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
12.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Illumina
13.1.1 Illumina Company Details
13.1.2 Illumina Business Overview
13.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020))
13.1.5 Illumina Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview
13.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Knome
13.4.1 Knome Company Details
13.4.2 Knome Business Overview
13.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.4.5 Knome Recent Development
13.5 Genomatix Software
13.5.1 Genomatix Software Company Details
13.5.2 Genomatix Software Business Overview
13.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.5.5 Genomatix Software Recent Development
13.6 GATC Biotech
13.6.1 GATC Biotech Company Details
13.6.2 GATC Biotech Business Overview
13.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.6.5 GATC Biotech Recent Development
13.7 Oxford Nanopore Technologies
13.7.1 Oxford Nanopore Technologies Company Details
13.7.2 Oxford Nanopore Technologies Business Overview
13.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.7.5 Oxford Nanopore Technologies Recent Development
13.8 Macrogen
13.8.1 Macrogen Company Details
13.8.2 Macrogen Business Overview
13.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.8.5 Macrogen Recent Development
13.9 Life Technologies
13.9.1 Life Technologies Company Details
13.9.2 Life Technologies Business Overview
13.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.9.5 Life Technologies Recent Development
13.10 DNASTAR
13.10.1 DNASTAR Company Details
13.10.2 DNASTAR Business Overview
13.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.10.5 DNASTAR Recent Development
13.11 Exosome Diagnostics
10.11.1 Exosome Diagnostics Company Details
10.11.2 Exosome Diagnostics Business Overview
10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.11.5 Exosome Diagnostics Recent Development
13.12 Biomatters
10.12.1 Biomatters Company Details
10.12.2 Biomatters Business Overview
10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.12.5 Biomatters Recent Development
13.13 CLC Bio
10.13.1 CLC Bio Company Details
10.13.2 CLC Bio Business Overview
10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.13.5 CLC Bio Recent Development
13.14 BGI
10.14.1 BGI Company Details
10.14.2 BGI Business Overview
10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.14.5 BGI Recent Development
13.15 Qiagen
10.15.1 Qiagen Company Details
10.15.2 Qiagen Business Overview
10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.15.5 Qiagen Recent Development
13.16 Perkin Elmer
10.16.1 Perkin Elmer Company Details
10.16.2 Perkin Elmer Business Overview
10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.16.5 Perkin Elmer Recent Development
13.17 Pacific Bioscience
10.17.1 Pacific Bioscience Company Details
10.17.2 Pacific Bioscience Business Overview
10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.17.5 Pacific Bioscience Recent Development
13.18 Partek
10.18.1 Partek Company Details
10.18.2 Partek Business Overview
10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.18.5 Partek Recent Development
13.19 GnuBIO
10.19.1 GnuBIO Company Details
10.19.2 GnuBIO Business Overview
10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.19.5 GnuBIO Recent Development
13.20 Foundation Medicine
10.20.1 Foundation Medicine Company Details
10.20.2 Foundation Medicine Business Overview
10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.20.5 Foundation Medicine Recent Development
13.21 Paradigm
10.21.1 Paradigm Company Details
10.21.2 Paradigm Business Overview
10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.21.5 Paradigm Recent Development
13.22 Caris Life Sciences
10.22.1 Caris Life Sciences Company Details
10.22.2 Caris Life Sciences Business Overview
10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.22.5 Caris Life Sciences Recent Development
13.23 Myriad Genetics
10.23.1 Myriad Genetics Company Details
10.23.2 Myriad Genetics Business Overview
10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.23.5 Myriad Genetics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Clinical Oncology Next Generation Sequencing (NGS) Key Market Segments
Table 2. Key Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
Table 3. Ranking of Global Top Clinical Oncology Next Generation Sequencing (NGS) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of NGS Pre-Sequencing
Table 6. Key Players of Sequencing
Table 7. Key Players of NGS Data Analysis
Table 8. Key Players of Primary, Secondary & Tertiary Data Analysis
Table 9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2015-2020)
Table 13. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
Table 19. Main Points Interviewed from Key Clinical Oncology Next Generation Sequencing (NGS) Players
Table 20. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Players (2015-2020) (Million US$)
Table 21. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players (2015-2020)
Table 22. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2019)
Table 23. Global Clinical Oncology Next Generation Sequencing (NGS) by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
Table 26. Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Type (2015-2020)
Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2021-2026)
Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Application (2015-2020)
Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 33. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Application (2021-2026)
Table 34. North America Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 36. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 37. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 38. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 39. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 40. Europe Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 42. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 44. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 46. China Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 47. China Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 48. China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 49. China Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 50. China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 51. China Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 52. Japan Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 54. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 56. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 60. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 62. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 64. India Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 65. India Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 66. India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 67. India Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 68. India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 69. India Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Clinical Oncology Next Generation Sequencing (NGS) Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Clinical Oncology Next Generation Sequencing (NGS) Market Share (2019-2020)
Table 72. Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2015-2020)
Table 74. Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2015-2020)
Table 76. Illumina Company Details
Table 77. Illumina Business Overview
Table 78. Illumina Product
Table 79. Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 80. Illumina Recent Development
Table 81. Roche Company Details
Table 82. Roche Business Overview
Table 83. Roche Product
Table 84. Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 85. Roche Recent Development
Table 86. Agilent Technologies Company Details
Table 87. Agilent Technologies Business Overview
Table 88. Agilent Technologies Product
Table 89. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 90. Agilent Technologies Recent Development
Table 91. Knome Company Details
Table 92. Knome Business Overview
Table 93. Knome Product
Table 94. Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 95. Knome Recent Development
Table 96. Genomatix Software Company Details
Table 97. Genomatix Software Business Overview
Table 98. Genomatix Software Product
Table 99. Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 100. Genomatix Software Recent Development
Table 101. GATC Biotech Company Details
Table 102. GATC Biotech Business Overview
Table 103. GATC Biotech Product
Table 104. GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 105. GATC Biotech Recent Development
Table 106. Oxford Nanopore Technologies Company Details
Table 107. Oxford Nanopore Technologies Business Overview
Table 108. Oxford Nanopore Technologies Product
Table 109. Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 110. Oxford Nanopore Technologies Recent Development
Table 111. Macrogen Business Overview
Table 112. Macrogen Product
Table 113. Macrogen Company Details
Table 114. Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 115. Macrogen Recent Development
Table 116. Life Technologies Company Details
Table 117. Life Technologies Business Overview
Table 118. Life Technologies Product
Table 119. Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 120. Life Technologies Recent Development
Table 121. DNASTAR Company Details
Table 122. DNASTAR Business Overview
Table 123. DNASTAR Product
Table 124. DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 125. DNASTAR Recent Development
Table 126. Exosome Diagnostics Company Details
Table 127. Exosome Diagnostics Business Overview
Table 128. Exosome Diagnostics Product
Table 129. Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 130. Exosome Diagnostics Recent Development
Table 131. Biomatters Company Details
Table 132. Biomatters Business Overview
Table 133. Biomatters Product
Table 134. Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 135. Biomatters Recent Development
Table 136. CLC Bio Company Details
Table 137. CLC Bio Business Overview
Table 138. CLC Bio Product
Table 139. CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 140. CLC Bio Recent Development
Table 141. BGI Company Details
Table 142. BGI Business Overview
Table 143. BGI Product
Table 144. BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 145. BGI Recent Development
Table 146. Qiagen Company Details
Table 147. Qiagen Business Overview
Table 148. Qiagen Product
Table 149. Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 150. Qiagen Recent Development
Table 151. Perkin Elmer Company Details
Table 152. Perkin Elmer Business Overview
Table 153. Perkin Elmer Product
Table 154. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 155. Perkin Elmer Recent Development
Table 156. Pacific Bioscience Company Details
Table 157. Pacific Bioscience Business Overview
Table 158. Pacific Bioscience Product
Table 159. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 160. Pacific Bioscience Recent Development
Table 161. Partek Company Details
Table 162. Partek Business Overview
Table 163. Partek Product
Table 164. Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 165. Partek Recent Development
Table 166. GnuBIO Company Details
Table 167. GnuBIO Business Overview
Table 168. GnuBIO Product
Table 169. GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 170. GnuBIO Recent Development
Table 171. Foundation Medicine Company Details
Table 172. Foundation Medicine Business Overview
Table 173. Foundation Medicine Product
Table 174. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 175. Foundation Medicine Recent Development
Table 176. Paradigm Company Details
Table 177. Paradigm Business Overview
Table 178. Paradigm Product
Table 179. Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 180. Paradigm Recent Development
Table 181. Caris Life Sciences Company Details
Table 182. Caris Life Sciences Business Overview
Table 183. Caris Life Sciences Product
Table 184. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 185. Caris Life Sciences Recent Development
Table 186. Myriad Genetics Company Details
Table 187. Myriad Genetics Business Overview
Table 188. Myriad Genetics Product
Table 189. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020) (Million US$)
Table 190. Myriad Genetics Recent Development
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type: 2020 VS 2026
Figure 2. NGS Pre-Sequencing Features
Figure 3. Sequencing Features
Figure 4. NGS Data Analysis Features
Figure 5. Primary, Secondary & Tertiary Data Analysis Features
Figure 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
Figure 7. Academic & Clinical Research Case Studies
Figure 8. Hospitals & Clinics Case Studies
Figure 9. Pharma & Biotech Entities Case Studies
Figure 10. Clinical Oncology Next Generation Sequencing (NGS) Report Years Considered
Figure 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions: 2020 VS 2026
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players in 2019
Figure 16. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
Figure 18. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed

以下、関連資料のご紹介

次世代シーケンシング（NGS）の世界市場（～2026年）

Global Next Generation Sequencing (NGS) Market Size, Status and Forecast 2020-2026
MRC2-11QY03979 2020年11月20日 129Pages
当調査資料は次世代シーケンシング（NGS）のグローバル市場について調査・分析したレポートです。種類別（消耗品、プラットフォーム、サービス）市場規模、用途別（学術・政府研究所、製薬会社、バイオテクノロジー会社、病院＆クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリ...

次世代シーケンシング（NGS）データ分析の世界市場（～2026年）

Global Next Generation Sequencing (NGS) Data Analysis Market Size, Status and Forecast 2020-2026
MRC2-11QY03978 2020年11月20日 90Pages
当調査資料は次世代シーケンシング（NGS）データ分析のグローバル市場について調査・分析したレポートです。種類別（合成時解読法（SBS）技術、単一分子リアルタイムシーケンシング（SMRT）技術、イオン半導体シーケンシング技術、その他）市場規模、用途別（病院、バイオテクノロジー/製薬会社、学術研究所、委...

次世代シーケンサーの世界市場（～2026年）

Global Next Generation Sequencers Market Size, Status and Forecast 2020-2026
MRC2-11QY03977 2020年11月20日 96Pages
当調査資料は次世代シーケンサーのグローバル市場について調査・分析したレポートです。種類別（合成時解読法（SBS）、イオン半導体シーケンシング、ライゲーションによるシーケンシング（SBL）、パイロシーケンシング、単一分子リアルタイム（SMRT）シーケンシング、その他）市場規模、用途別（診断、創薬、バイ...

臨床試験（CTMS）の世界市場（～2026年）

Global Clinical Trial (CTMS) Market Size, Status and Forecast 2020-2026
MRC2-11QY11399 2020年11月25日 99Pages
当調査資料は臨床試験（CTMS）のグローバル市場について調査・分析したレポートです。種類別（クラウド型（SaaS）CTMS、エンタープライズライセンス（オンプレミス）CTM、ウェブ型（ホスト）CTMS）市場規模、用途別（臨床研究機関（CRO）、医療機器会社、製薬・バイオ技術会社、その他エンドユーザー...

自動発電制御（AGC）の世界市場（～2026年）

Global Automatic Generation Control Market Size, Status and Forecast 2020-2026
MRC2-11QY10947 2020年11月25日 98Pages
当調査資料は自動発電制御（AGC）のグローバル市場について調査・分析したレポートです。種類別（タービンガバナー制御（TGC）、負荷周波数制御（LFC））市場規模、用途別（水力発電所、火力発電所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

免疫レパートリーシーケンスの世界市場（～2026年）

Global Immune Repertoire Sequencing Market Size, Status and Forecast 2020-2026
MRC2-11QY12308 2020年11月25日 94Pages
当調査資料は免疫レパートリーシーケンスのグローバル市場について調査・分析したレポートです。種類別（パイロシーケンシング、色素終結シーケンシング、半導体シーケンシング、その他）市場規模、用途別（バイオマーカー発見、感染症、ワクチン開発・有効性、癌免疫療法、自己免疫疾患、移植片拒絶反応・耐性、その他）市...

次世代車載ネットワーク（IVN）の世界市場（～2026年）

Global Next Generation In-Vehicle Networking (IVN) Market Size, Status and Forecast 2020-2026
MRC2-11QY03976 2020年11月20日 130Pages
当調査資料は次世代車載ネットワーク（IVN）のグローバル市場について調査・分析したレポートです。種類別（配線、リレー、スイッチ、センサーメモリ、その他）市場規模、用途別（気候制御、ナビゲーション、運転支援システム（DAS））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

メタゲノムシーケンスの世界市場（～2026年）

Global Metagenomic Sequencing Market Size, Status and Forecast 2020-2026
MRC2-11QY12659 2020年11月25日 99Pages
当調査資料はメタゲノムシーケンスのグローバル市場について調査・分析したレポートです。種類別（シーケンシング、バイオインフォマティクス）市場規模、用途別（感染症診断、環境修復、腸内微生物特性評価、バイオテクノロジー、バイオ燃料、エコロジー、農業）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ...

メタゲノミクスシーケンスの世界市場（～2026年）

Global Metagenomics Sequencing Market Size, Status and Forecast 2020-2026
MRC2-11QY12660 2020年11月25日 90Pages
当調査資料はメタゲノミクスシーケンスのグローバル市場について調査・分析したレポートです。種類別（機器、ソフトウェア、消耗品）市場規模、用途別（感染症診断、環境修復、腸内微生物特性評価、バイオテクノロジー、バイオ燃料、農業）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

次世代インプラント（NGI）の世界市場（～2026年）

Global Next Generation Implants (NGI) Market Size, Status and Forecast 2020-2026
MRC2-11QY03974 2020年11月20日 127Pages
当調査資料は次世代インプラント（NGI）のグローバル市場について調査・分析したレポートです。種類別（金属・金属合金、セラミックス、ポリマー、生物製剤、その他）市場規模、用途別（整形外科用インプラント、心臓血管用インプラント、眼用インプラント、歯科用インプラント）市場規模、地域別（北米、米国、カナダ、...

次世代シーケンシング（NGS）データ分析の世界市場（～2026年） North America is home to several well-established organizations of NGS data analysis. A significant number of NGS research projects are being carried out in Canadian universities, which in turn has resulted into huge demand for NGS data analysis, thereby affecting the revenue growth in the region. N…
次世代シーケンシング（NGS）の世界市場（～2026年） NGS is a technology in which millions and billions of DNA strands can be sequenced through massive parallelization. This technique is also known as high throughput sequencing. The impact of the driving factors is expected to overcome the effect of restraints. Moreover, the utilization of cloud compu…
メタゲノムシーケンスの世界市場（～2026年） Metagenomics is the study of genetic material recovered directly from environmental samples. The broad field may also be referred to as environmental genomics, ecogenomics or community genomics. As the price of DNA sequencing continues to fall, metagenomics now allows microbial ecology to be investi…
免疫レパートリーシーケンスの世界市場（～2026年） Immune Repertoire is the collection of B and T cells with functional diversity in the body that reflects the immune selectivity. Immune Repertoire Sequencing means to sequence the complimentary determining region of both B-cell receptor and T-cell receptor. Immune receptor repertoire profiling portr…
メタゲノミクスシーケンスの世界市場（～2026年） Metagenomics is the process of cloning and analyzing the genomes of an organism without culturing them in a community. The major factors driving the growth of the global metagenomics market include technological advancements in DNA sequencing. Moreover, metagenomics is applicable across a broad rang…